The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PGNX Detailed Price Forecast - CNN Money||View PGNX Detailed Summary - Google Finance|
|View PGNX Detailed Summary - Yahoo! Finance||View PGNX Stock Research & Analysis - Zacks.com|
|View PGNX Trends & Analysis - Trade-Ideas||View PGNX Major Holders - Barrons|
|View PGNX Call Transcripts - NASDAQ||View PGNX Breaking News & Analysis - Seeking Alpha|
|View PGNX Annual Report - CompanySpotlight.com||View PGNX OTC Short Report - OTCShortReport.com|
|View PGNX Fundamentals - TradeKing||View PGNX SEC Filings - Bar Chart|
|View Historical Prices for PGNX - The WSJ||View Performance/Total Return for PGNX - Morningstar|
|View the Analyst Estimates for PGNX - MarketWatch||View the Earnings History for PGNX - CNBC|
|View the PGNX Earnings - StockMarketWatch||View PGNX Buy or Sell Recommendations - MacroAxis|
|View the PGNX Bullish Patterns - American Bulls||View PGNX Short Pain Metrics - ShortPainBot.com|
|View PGNX Stock Mentions - StockTwits||View PGNX Stock Mentions - PennyStockTweets|
|View PGNX Stock Mentions - Twitter||View PGNX Investment Forum News - Investor Hub|
|View PGNX Stock Mentions - Yahoo! Message Board||View PGNX Stock Mentions - Seeking Alpha|
|View Insider Transactions for PGNX - SECform4.com||View Insider Transactions for PGNX - Insider Cow|
|View PGNX Major Holdings Summary - CNBC||View Insider Disclosure for PGNX - OTC Markets|
|View Insider Transactions for PGNX - Yahoo! Finance||View Institutional Holdings for PGNX - NASDAQ|
|View PGNX Stock Insight & Charts - FinViz.com||View PGNX Investment Charts - StockCharts.com|
|View PGNX Stock Overview & Charts - BarChart||View PGNX User Generated Charts - Trading View|
Steven Cohen Storms Into Progenics Pharmaceuticals
Posted on Thursday January 03, 2019
Point72 asset manager adds cancer-treating company to pile of health care positions
Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
Posted on Wednesday January 02, 2019
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, and Curium today announced an exclusive agreement to develop and commercialize PyL in Europe. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent designed to visualize prostate cancer currently in Phase 3 development.
Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer
Posted on Wednesday January 02, 2019
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D. to the newly created role of Chief Medical Officer. Dr. Das brings 13 years of drug development experience, including leading activities related to the approval and launch of Avastin® in multiple indications at Genentech, as well as a decade of clinical practice and academic expertise in neurology and neuro-oncology. “Asha is a talented clinician and a proven oncology drug development leader,” stated Mark Baker, CEO of Progenics. “Her experience developing and executing registrational studies will be invaluable to Progenics as we advance our portfolio of PSMA-targeted imaging and therapeutic agents and look to developing new indications for AZEDRA.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
Posted on Wednesday December 12, 2018
Today, we look at a slightly riskier part of the sector in promising small caps that should be able to reach profitability with little to no additional funding needs. Revenues should more than double this year to over $140 million as the genetic test market continues to expand rapidly and Invitae garners market share. The company is doing a good job lessening its cash burn every quarter and is on the path to reach profitability late in 2019.